Pharmacology
All Targets
7-TM Receptors
Ion Channels
Nuclear Receptors
Enzyme-Linked Receptors
Transporters
Enzymes
Other Pharmacology
Cellular Processes
Angiogenesis
Apoptosis
Cell Cycle
Cell Metabolism
Cytoskeleton & Motor Proteins
ECM & Adhesion Molecules
Epigenetics
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
5-HT Transporters
More Information »5-HT transporters (serotonin transporters, SERT) are sodium- and chloride-dependent members of the solute carrier family 6 (SLC6) found widely distributed throughout the brain. They are responsible for re-uptake of 5-HT and undergo a conformational change to move molecules.
5-HT Transporter Products
Inhibitors |
|
Cat.No. |
Product Name / Activity |
| 2341 | A 80426 mesylate |
| 5-HT uptake inhibitor and α2 antagonist | |
| 4456 | Amitriptyline hydrochloride |
| 5-HT and noradrenalin re-uptake inhibitor | |
| 4357 | Bicifadine hydrochloride |
| Noradrenalin, 5-HT and dopamine re-uptake inhibitor | |
| 2322 | BTS 54-505 hydrochloride |
| Potent SNRI; active metabolite of sibutramine (Cat. No. 2290) | |
| 1427 | Citalopram hydrobromide |
| Highly potent and selective 5-HT uptake inhibitor | |
| 0457 | Clomipramine hydrochloride |
| 5-HT re-uptake inhibitor | |
| 2833 | Cocaine hydrochloride |
| Inhibitor of monoamine transporters | |
| 4358 | Dapoxetine hydrochloride |
| Selective serotonin reuptake inhibitor | |
| 2695 | Dexfenfluramine hydrochloride |
| 5-HT re-uptake inhibitor. Also stimulates 5-HT release | |
| 3428 | DMT |
| SERT inhibitor. Also endogenous σ1 ligand and 5-HT2A agonist | |
| 4798 |
(S)-Duloxetine hydrochloride
|
| Potent 5-HT and NE reuptake inhibitor; also blocks dopamine reuptake | |
| 4796 |
Escitalopram oxalate
|
| Selective serotonin reuptake inhibitor (SSRI) | |
| 0927 | Fluoxetine hydrochloride |
| 5-HT re-uptake inhibitor | |
| 1033 | Fluvoxamine maleate |
| 5-HT re-uptake inhibitor | |
| 1588 | Indatraline hydrochloride |
| Potent 5-HT uptake inhibitor. Also inhibits dopamine and noradrenalin uptake | |
| 2545 | Lofepramine |
| 5-HT and noradrenalin re-uptake inhibitor (SNRI) | |
| 3350 | LY 393558 |
| Dual 5-HT re-uptake inhibitor and 5-HT1B/1D antagonist | |
| 2148 | (±)-McN 5652 |
| Potent, orally active 5-HT uptake inhibitor. Also inhibits noradrenalin and dopamine uptake in vitro | |
| 3027 | (±)-MDMA hydrochloride |
| Inhibitor of 5-HT and dopamine uptake; hallucinogenic | |
| 4443 | Mephedrone hydrochloride |
| Inhibits synaptosomal dopamine and 5-HT uptake | |
| 3286 | Milnacipran hydrochloride |
| 5-HT and noradrenalin re-uptake inhibitor (SNRI) | |
| 2777 | Nefazodone hydrochloride |
| 5-HT uptake inhibitor and 5-HT2A antagonist. Antidepressant | |
| 2141 | Paroxetine maleate |
| Highly potent and selective 5-HT uptake inhibitor | |
| 2395 | Sertraline hydrochloride |
| 5-HT re-uptake inhibitor | |
| 2290 | Sibutramine hydrochloride |
| 5-HT and noradrenalin re-uptake inhibitor (SNRI) | |
| 2175 | Tetrabenazine |
| Potent inhibitor of vesicular monoamine transport; depletes 5-HT stores | |
| 2917 | Venlafaxine hydrochloride |
| Dual serotonin/noradrenalin re-uptake inhibitor | |
| 4194 | WY 45233 succinate |
| Dual serotonin/noradrenalin re-uptake inhibitor | |
| 1767 | Zimelidine dihydrochloride |
| Selective 5-HT uptake inhibitor | |
Ligand Sets |
|
Cat.No. |
Product Name / Activity |
| 1877 | Serotonin Uptake Inhibitor Tocriset™ |
| Selection of 4 serotonin uptake inhibitors (Cat. Nos. 1427, 0457, 0927 and 1033) | |
Other |
|
Cat.No. |
Product Name / Activity |
| 3547 | Serotonin hydrochloride |
| Endogenous substrate | |
| 1972 | Tianeptine sodium salt |
| Selective facilitator of 5-HT uptake; antidepressant | |
Related Categories
Quick Order
Find multiple products by catalog number
Tocris Events
Win a Kindle
5th Conference on Advances in Molecular Mechanisms Underlying Neurological Disorders
June 23 - 26, 2013
Bath, UK



